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Rainer Storb,1 Joseph H. Antin,2 Corey Cutler2In a rapidly developing field, one can always anticipate that different interpretations of similar data will coex-
ist. Stem cell transplanters can be a contentious lot, especially in the absence of controlled randomized trials.
Thus, although improvements in the basic understanding of acute graft-versus-host disease (aGVHD) has led
to many testable hypotheses in the management of GVHD, there remains little consensus regarding the most
effective and least toxic approach to GVHD prevention. In the 1980s, the comparison would have been be-
tween cyclosporine-based regimens and ex vivo T cell depletion (TCD). Although ex vivo TCD is still used in
some settings, pharmacologic-based therapy and in vivo TCD with serotherapy now predominate. This re-
view is meant to highlight the advantages and disadvantages of the ‘‘standard of care’’ and assess the prospects
for future regimens that may be more effective.
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Rainer Storb, MD
Graft-versus-host disease (GVHD) has been the
Achilles heel of allogeneic hematopoietic cell trans-
plantation (HCT) since its first description in the
1950s (reviewed in [1]). It is caused by immune
reactions of donor T cells against disparate host
histocompatibility antigens. Most graft-versus-host
(GVH) reactions are undesirable, and cause disease
in skin, gut, and liver as principal target organs.
One reaction, directed at hematopoietic tissue
targets, is desirable and indispensable for the cure
of hematologic malignancies, but difficult to separate
from GVHD. Donor T cell immunity can be trig-
gered by both major and minor histocompatibility
differences. The latter observation made in the late
1960s in dogs given marrow grafts from DLA-identi-
cal littermates [2,3] was unpredicted and prompted
the search for immunosuppressive drugs capable of1Fred Hutchinson Cancer Research Center, University of
ington, Seattle, Washington; and 2Harvard Medical
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6/j.bbmt.2009.10.016averting or at least mitigating the often violent
GVH reactions.
Most then known immunosuppressive agents, alky-
lators, and antimetabolites were screened for efficacy in
animal models during the late 1960s and early 1970s,
either given alone or in combinations. Many of them
showed toxicities to the gastrointestinal (GI) tract, the
liver, or themarrow graft, which led to their elimination
from further investigation. One of the drugs, the folate
antagonist methotrexate (MTX), emerged the winner.
Studies, first byUphoff [4] inmice and thenby the Storb
et al. [5] indogs, showed significant reduction inGVHD
severity, prolongation of survival, and occasional long-
term survivors, even among major histocompatibility
complex (MHC)-mismatched graft recipients. Presum-
ably, this resulted from a dramatic effect of MTX on
grafteddonor lymphocytes attempting to replicate in re-
sponse to encountering antigens on host target tissues.
For the best effect, MTX dosing was begun not before
24 hours after HCT had elapsed. Owing to its GI side
effects, further MTX doses were spaced, eventually re-
sulting in theday 1, 3, 6, 11, and thenonceweekly sched-
ule that entered clinical trials in the late 1960s and
remained ‘‘standard’’ through the 1970s [6]. Even under
the best of circumstances, HLA-identical sibling mar-
row grafts for aplastic anemia (AA) patients conditioned
with cyclophosphamide (Cy), a 15% incidence of grade
III and a 10% incidence of grade IV acute GVHD
(aGVHD) were seen [7,8].
A clinical pilot study with the first calcineurin in-
hibitor, cyclosporine (CsA), was reported by Powles
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showed equivalency between MTX and CsA in regard
to aGVHD prevention [10]. This was confirmed in
three prospective clinical trials in patients given
HLA-identical sibling grafts for hematologic malig-
nancies [11]. Mortality from GVHD-related compli-
cations continued to remain high.
Consequently, combinations and different sched-
ules of several antimetabolites and CsA were explored
in dogs in hopes of identifying superior regimens [12].
Of all combinations and schedules tested, a short
course of MTX with an extended course of CsA
showed clear evidence of synergism between the 2
drugs and resulted in impressive improvement of sur-
vival in recipient dogs [13]. Two small randomized,
prospective clinical trials, 1 in patients with AA and
the other in patients with acute or chronic myeloge-
nous leukemia (AML, CML) given HLA-identical sib-
ling grafts, showed MTX/CsA to be significantly
better both in preventing aGVHD and improving sur-
vival than either drug alone [14,15]. Both trials were
published in 1986 with follow-up reported in 2005
[16,17]. Grade IV aGVHD was not seen in patients
given MTX/CsA in either study, and grade III disease
was the exception, whereas patients given single agent
prophylaxis experienced 38% (MTX) and 26% (CsA)
grades III-IV aGVHD, respectively. Disappointingly,
no improvements were seen with regard to chronic
GVHD (cGVHD). Moreover, some concern was
raised that patients with AML given MTX/CsA might
have a slightly higher rate of leukemic relapse than
their CsA-treated counterparts, but differences were
not statistically significant, possibly because of small
patient numbers in each arm.
When MTX/CsA was used in early unrelated
HCT (‘‘archaic’’ HLA typing: donors chosen by sero-
logic testing for HLA-A and -B and mutual nonreac-
tivity of their cells in mixed leukocyte culture) and
HLA-mismatched related grafts, results were some-
what disappointing, and comparatively high rates of
severe aGVHD were seen. Attempts to improve out-
comes of HCT by adding prednisone to the MTX/
CsA combination did not yield convincingly positive
results [18-20].
In the early 1990s, another calcineurin inhibitor,
tacrolimus (FK-506), promised wonders in the liver
transplantation field [21]. However, studies in the ca-
nine HCT model showed FK-506 alone to be no bet-
ter than either MTX or CsA alone, even when it was
combined with prednisone [22,23]. Not surprisingly
and reminiscent of the CsA experience more than a de-
cade earlier, combining FK-506 with a short course of
MTX led to impressive improvement in survival of ca-
nine recipients [22]. These preclinical findings led to
several Phase I/II clinical trials, which were followed
by 2 multicenter, randomized, prospective trials com-
paring MTX/CsA to MTX/FK-506, 1 in HLA-identi-cal sibling recipients [24] and the other in recipients of
HLA-matched unrelated grafts [25]; all patients in the
2 trials had hematologic malignancies. Both trials
showed reductions in the overall incidence of aGVHD
(but not cGVHD) among patients in the MTX/FK-
506 arms compared to MTX/CsA. However, surpris-
ingly, survival of MTX/FK-506-treated patients was
not better than that of patients given MTX/CsA; in
fact, it was slightly worse in the trial involving HLA-
identical sibling grafts. The outcomes of the 2 trials
prompted some transplant centers to become propo-
nents of MTX/FK-506, whereas others continued us-
ing MTX/CsA. As for use of the latter, Figures 1 and 2
give examples of survivals in patients with AA and
CML given MTX/CsA prophylaxis after HLA-
matched related or unrelated HCT.
Another agent, mycophenolate mofetil (MMF),
whose metabolite mycophenolic acid inhibits prolifer-
ation of lymphocytes, was also highly synergistic in
dogs when combined with CsA, both in preventing
aGVHD [26] and enhancing hematopoietic engraft-
ment after nonmyeloablative (NMA) conditioning
[27]. The combination is now widely used for patients
receiving reduced-intensity conditioning (RIC) regi-
mens (reviewed in [28]). Serious (grade III-IV)
aGVHD was seen in 4% to 5% of HLA-matched
related [29] and 10% of HLA-matched unrelated
recipients [30] given NMA conditioning. However,
prevention of aGVHD was not improved with
MMF/CsA in human myeloablative (MA) recipients
when compared to MTX/CsA [31,32]. Yet another
study showed improved prevention of aGVHD when
the agent rapamycin (sirolimus) was combined with
MTX/CsA [33], whereas a more recent study did not
confirm this result [34]. Of note, combining the non-
toxic drug ursodiol with MTX/CsA, MTX/FK-506
or MMF/CsA GVHD prevention, although not re-
ducing the overall incidence of aGVHD, has led to
a remarkable reduction in liver GVHD and perhaps
also nonrelapse mortality (NRM) [35].CONCLUSIONS
The combination of MTX and a calcineurin inhib-
itor originated in preclinical canine studies from the
early 1980s and 1990s, and has been in clinical use for
more than a quarter century. It has led to outstanding
survival rates afterHLA-identical sibling grafts, for ex-
ample, in patients with AA and CML. It has been
slightly less effective for unrelated transplantations
and noticeably less effective for HLA-mismatched
grafts. For patients with hematologic malignancies,
MTX/CsA or MTX/FK-506 seems to have struck
a reasonable balance between preventing undesirable
GVH reactions and retaining desirable graft-versus-
tumor (GVT) effects. Yet, the drug combination is
Figure 1. Survival and cGVHD in patients with aplastic anemia (2-63
years old) given HLA matched-related grafts and receiving MTX/CsA
after conditioning with cyclophosphamide and antithymocyte globulin
(Cy/ATG) [87]. Similar results have been reported in children by Loca-
telli et al. [88].
Figure 2. Survival of patients with chronic myelogenous leukemia in
chronic phase (CML-CP) given HLA-matched unrelated HCT and re-
ceiving MTX/CsA after conditioning with cyclophosphamide and total
body irradiation (Cy/TBI) [89]. This represents a subgroup of patients
who received prophylaxis with fluconazole and ganciclovir.
S20 Biol Blood Marrow Transplant 16:S18-S27, 2010R. Storb et al.far from ideal. The immunosuppressive agents have
numerous side effects, have to be given for extended pe-
riods of time, delay immunologic recovery, and more-
over, are not uniformly effective, with many patients
still dying from aGVHDand associated complications.
So far, attempts at improving on MTX/CsA or MTX/
FK-506 have met with only equivocal success. The
ideal of GVHD prevention would consist of causing
apoptotic death of all host-reactive donor lymphocytes
within days of HCT while leaving donor T cells with
memory for pathogens unscathed, thereby inducing
graft-host tolerance while allowing for rapid recovery
of other immune functions. An example of such an ap-
proach has been reported for HLA-haploidentical re-
lated grafts with administration of high doses of Cy 3
and 4 days after HCT [36]. The concern with this
and similar approaches in patients with hematologic
cancer, however, is an increased risk of relapse ofmalig-
nancies given the current lack of understanding of how
to discriminate between desirable GVT effects and un-
desirable GVHD. Until that understanding has been
attained, MTX/CsA or MTX/FK-506 may continue
to be standard of care.THE CASE AGAINST CALCINEURIN
INHIBITORS AND MTX
Corey Cutler, MD, MPH
Despite advances in all other aspects of transplant-
related technology over the past 20 years, the relatively
toxic regimen of a calcineurin inhibitor and MTX
remains the standard of care. The recent impetus to
find newer agents and regimens for GVHD prophy-
laxis has been driven largely by the adverse effects of
MTX, as well as insufficient control of GVHD
afforded by this drug.The use of posttransplant MTX may increase the
risk of significant complications of transplantation, in-
cluding oropharyngeal mucositis and diffuse alveolar
hemorrhage (DAH)/idiopathic pneumonia syndrome
[37,38]. As an antiproliferative agent, MTX use causes
a delay in the time to neutrophil and platelet engraft-
ment after transplantation [39]. Finally, as an agent
that can independently induce tissue injury, there is
a theoretic concern that MTX may paradoxically be
implicated in the steps of GVHD initiation by exacer-
bating tissue injury and augmenting the cytokine cas-
cade associated with GVHD [40].On the Use of FK-506
CsA and FK-506 share a final common pathway of
inhibition of interleukin (IL)-2-mediated T cell expan-
sion and cytotoxicity. The 2 compounds have non-
overlapping toxicity profiles, with FK-506 generally
being considered less toxic within its suggested thera-
peutic serum concentration range. Several lines of ev-
idence suggest that this agent is more effective than
CsA in GVHD prophylaxis. In a retrospective review
of 777 patients who underwent unrelated donor trans-
plantation, the rate of grade II-IV aGVHDwas 36.4%
in comparison with 57.8% for CsA patients, and this
led to an improvement in overall survival (OS) [41].
There is also anecdotal evidence of the utility of drug
switching from CsA to FK-506 in cases of resistant
GVHD [42-44].
Two large North American phase III studies have
been performed that compared the combination of
FK-506 and MTX with the combination of CsA and
MTX in matched, related [24], and unrelated donor
marrow transplantation [25], as well as a third smaller
trial in Japan [45] (Table 1). In the matched related
donor (MRD) setting, 329 patients were randomized
to receive either FK-506 with MTX or CsA and MTX
and the incidence of grade II-IV aGVHD was 31.9%
in the FK-506 arm and 44.4% in the CsA arm (adjusted
Table 1. Summary of Randomized Trials of Novel GVHD Regimens
Sample Size Grade II-IV Acute GVHD Grade III-IV Acute GVHD Chronic GVHD
Ratanatharathorn, 1998 [24]
CsA/MTX 164 44.4% 17.1% 55.9%
Tac/MTX 165 31.9%* 13.3% 49.4%
Nash, 2000 [25]
CsA/MTX 90 74% 25.5% 70%
Tac/MTX 90 56%* 17.7%* 76%
Hiraoka, 2001 [45]
CsA/MTX 65 48.0% 21.1% 47.8%
Tac/MTX 66 17.5%* 9.5% 47.3%
Bolwell, 2004 [31]
CsA/MTX 19 37% — 64%
CsA/MMF 21 48% — 63%
Finke, 2008 [54]
CsA/MTX 98 51.0% 24.5% 58.8%
CsA/MTX/ATG 103 33.0%* 11.7% 30.8%*
Perkins, 2008 [60]
Tac/MTX 47 79% 4% 45%
Tac/MMF 42 78% 19%* 38%
GVHD indicates graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate; Tac, tacrolimus; MMF, mycophenolate mofetil; ATG, antithymocyte
globulin. * p < 0.05.
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toxicity and adverse renal outcomes were related to the
dosing strategy of FK-506, where trough levels up to 40
ng/mL were considered acceptable, and resulted in an
excess of treatment-related deaths. In contrast, 27%
of deaths in the CsA arm were related to GVHD,
whereas only 10%of deaths in the FK-506 armwere re-
lated toGVHD. Randomization in this trial was imbal-
anced, with more patients with advanced malignancies
assigned to the FK-506 arm (and who also had a trend
to receive more intense conditioning regimens) and as
such, no difference in OS was demonstrable among
standard-risk patients. A matched pair analysis demon-
strated that differences in the combination of diagnosis,
disease status, and age between the 2 treatment arms
within the advanced disease group of patients con-
founded the analysis of survival in advanced-stage pa-
tients [46].
In the matched unrelated donor (MUD) random-
ized trial, the rate of grade II-IV aGVHD was 56%
among patients randomized to FK-506 and 74%
among patients randomized to receive CsA (P 5
.0002). In addition, there was a decrease in the severity
of aGVHD in the FK-506 group (P5 .005), leading to
a decrease in the cumulative dose of corticosteroids by
day 105 in the FK-506 arm (P5 .016), and a 4-fold de-
crease in the rate of GVHD related-death (13.3% ver-
sus 3.3%). The incidence of adverse renal outcomes in
the FK-506-treated patients in this trial was more
modest compared to the related donor trial, likely re-
lated to a slightly narrower serum target trough con-
centration. However, analysis of drug concentration
and outcomes suggested that 10 to 20 ng/mL may be
the optimal level [47,48].
The Japanese study, reported by Hiraoka et al.
[45], randomly assigned 131 patients to receive either
FK-506 or CsA. One hundred twelve of thesepatients (56 in each group) received concomitant
MTX, and the remaining patients received either cor-
ticosteroids or no additional immunosuppression, in
a balanced fashion. The incidence of aGVHD in the
FK-506 arm was significantly lower than the CsA
arm (17.5% versus 48%, P\ .0001), and these findings
were consistent in both related and alternative donor
subgroups. Although treatment discontinuation be-
cause of medication adverse events was higher in the
FK-506 group, no patient required hemodialysis.
This is likely attributable to the lower serum trough
concentration goals (20-25 ng/mL for 2-3 weeks,
10-15 ng/mL thereafter) in this trial.How Effective Can Therapy Be, If It Cannot Be
Delivered?
For any therapy to be effective, it must be delivered
in a consistent manner, according to plan. Unfortu-
nately, MTX doses are commonly omitted after trans-
plantation because of ongoing toxicity or the concern
over increased toxicity related to its ongoing usage.
In 2 large randomized North American trials [24,25],
the rate of successful delivery ofMTX (4 doses totaling
45 mg/m2) was only 67.4% (66.2% in combination
with FK-506, 68.5% in combination with CsA). This
inability to deliver effective prophylaxis is highly rele-
vant, because the omission of the fourth dose of MTX
may be associated with an increased risk of aGVHD
[39,49,50].Advances Beyond Calcineurin-MTX
Combinations
Given the inadequacies of MTX as a GVHD pro-
phylaxis agent, several groups have embarked on
research efforts to replace this compound. Several
programs are highlighted here.
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Although most strategies to prevent and treat
aGVHD focus on blocking T cell proliferation, target-
ing the cytokine pathways that lead to the upregulation
of alloreactive T cells is seldom considered. The first
cytokine blockade protocol added IL-1 receptor antag-
onist to conventional FK-506/MTX in a randomized
double-blind trial [51]. No benefit was observed in
this study despite promising results in phase II trials
[52]. Another cytokine worth targeting is tumor necro-
sis factor (TNFa). TNFa is thought to be 1 of the crit-
ical cytokine regulators involved in the GVHD
cytokine cascade, and as such represents a potential
target in GVHD prophylaxis. The TNFa inhibitor
etanercept has been demonstrated to be efficacious in
the treatment of aGVHD [53]. Because it has been
demonstrated that levels of the TNFa receptor (used
as a surrogate for circulating TNFa) rise in advance
of aGVHD, the Michigan group have now tested
etanercept as part of a GVHD prophylaxis regimen.
Etanercept consists of 2 p75 portions of the TNFa
receptor covalently linked to the Fc portion of human
IgG and has a half-life of approximately 3 days after
subcutaneous dosing. In this phase II trial, etanercept
(0.4 m/kg, 25 mg maximum) was given twice weekly
commencing 1 week prior to transplantation, as induc-
tion-type immunotherapy, and continued for 18 doses.
In addition, FK-506 and minidose MTX (20 mg/m2
total) were administered, and 3 different MA regimens
were used. Overall, the rate of grade II-IV aGVHD
was 23%, and was as low as 11% when fludarabine
(Flu) and busulfan (Bu) were used for conditioning
(unpublished data kindly provided by S. Choi). One
hundred-day treatment-related mortality (TRM) was
16%, with no patient in the Flu-Bu arm succumbing
by day 100. Interestingly, outcomes were inversely re-
lated to the levels of TNFa, with patients who had the
lowest levels having the best outcomes, with the lowest
rates of aGVHD. Although this regimen does not
completely eliminate MTX, the inclusion of the cyto-
kine blocking drugs allows for a meaningful reduction
in the dose ofMTX that ultimately leads to a reduction
in TRM, and thus is promising.Antithymocyte globulin (ATG)
There are conflicting single-center data on the
value of additional ATG, and many centers use this
agent routinely in unrelated donor transplantation,
whereas others do not. The use of ATG in the peri-
transplant period can deplete both host and donor im-
mune cells, and although designed to reduce the
incidence and severity of aGVHD, ATG may also in-
crease malignant relapse rates by delaying antitumor
immunity development.
In a large randomized trial, patients who
underwent MA allogeneic stem cell transplantationfrom 8/8 matched unrelated donors were randomly
assigned to be given ATG in addition to CsA and
MTX. In this experience, there was a significant reduc-
tion in the rate of grade II-IV and grade III-IV
aGVHD favoring ATG use (33% versus 51%, P 5
.01; 11.7% versus 24.5%, P 5 .05) [54]. There was
a slight survival advantage in the ATG arm, which
did not attain statistical significance (59.2% versus
51.9%, P 5 .47).
Substitutions in Lieu of MTX
MMF
MMF has been studied extensively as an agent for
the prevention of aGVHD. MMF is the 2-morpholi-
noethyl ester of mycophenolic acid (MPA), a potent,
selective, and reversible inhibitor of inosine mono-
phosphate dehydrogenase that inhibits the de novo
pathway of guanosine nucleotide synthesis without
incorporation into DNA. Because T- and B-lympho-
cytes are critically dependent for their proliferation
on de novo synthesis of purines, MPA has potent cy-
tostatic effects on lymphocytes. Absorbed well after
oral administration, the optimal dose for use in trans-
plantation is unclear, with some centers administer-
ing it twice and others 3 times daily. The Seattle
group suggested an optimal dose of 45 mg/m2/day
in a phase I/II trial, where GVHD rates were similar
when compared with historic controls [32]. The dose-
limiting toxicities include reversible myelosuppres-
sion and mucosal toxicity of the GI tract causing
diarrhea, which can often clinically and histologically
resemble GVHD itself [55].
MMF has been used for GVHD prophylaxis in
combination with CsA [32,56], CsA with MTX [57],
and FK-506 [58]. In a retrospective review involving
93 patients, Neumann et al. [59] compared their
single-center experience of CsAwithMMF in compar-
ison with CsA and MTX [59]. There were trends to-
ward a reduced rate of grade II-IV aGVHD (38%
versus 61%) and improved OS (76% versus 55%),
although neither of these comparisons were statisti-
cally significant. However, there was a statistically sig-
nificant reduction in the time to neutrophil
engraftment (12 versus 18 days, P\ .0001).
In a small, single-center randomized trial, the
combination of CsA and MMF was compared with
CsA and MTX after Bu-based conditioning therapy
and marrow transplantation. Forty patients were ran-
domized prior to the early closure of the study. The
trial was discontinued prematurely because the combi-
nation of MMF and CsA was associated with faster he-
matopoietic engraftment (11 versus 18 days, P\ .001),
and decreased incidence of oropharyngeal mucositis
(median OMAS score 0.25 versus 1.0, P 5 .004) as
well as a reduction in the severity of the oropharyngeal
mucositis (21% versus 65%, P 5 .008). There was
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vival compared to CsA andMTX [31].With a superior
toxicity profile and comparative GVHD outcomes,
this regimen can be considered superior to, or at least
equivalent to, CsA and MTX.
A second small trial evaluated the combination of
FK-506 and MTX in comparison with FK-506 and
MMF for patients undergoing related or unrelated do-
nor transplantation. In an intent-to-treat analysis of 42
patients randomized toMMF and 47 patients random-
ized to MTX, no differences in the incidence of grade
II-IV GVHD were noted (79% in both arms), and
long-term outcome was the same in both arms as
well [60]. As in the prior MMF trial, this study demon-
strated a significant reduction in the incidence and se-
verity of oropharyngeal mucositis, MMF patients used
less narcotics and parenteral nutrition and had shorter
hospital stays (supplemental unpublished data kindly
provided by J. Perkins).Sirolimus
Used extensively at the Dana Farber Cancer
Institute (DFCI) since 2000, sirolimus is the first com-
mercially available mTOR inhibitor. It has immuno-
modulatory properties that extend far beyond T cell
inhibition to include effects on antigen presentation
cells, the thymus, and preservation of regulatory T
cell subsets after transplantation [61].
The initial experience demonstrated the safety of
this compound when added to FK-506 and MTX in
mismatched related and unrelated donor transplanta-
tion. In this trial involving 39 high-risk patients, the
rate of grade II-IV aGVHDwas only 26% [33]. In sub-
sequent phase II studies, the substitution of sirolimus
for MTX, in combination with FK-506, was shown
to lead to a rate of grade II-IV aGVHD of 20.5%,
with grade III-IV aGVHD occurring in under 5% of
patients [62]. No difference in outcome between recip-
ients of related or matched unrelated donors was
noted. These findings have been confirmed by several
groups [63-65]; however, the Seattle group, using siro-
limus in combination with MTX and CsA or FK-506,
were unable to replicate these findings [34]. This
smaller experience is flawed for several reasons, includ-
ing the use of concomitant MTX and Bu, both of
which increase treatment-related toxicity in this set-
ting [66], the timing of administration of the immuno-
suppressive regimen [63], and the use of CsA when
there is known synergy between sirolimus and FK-
506 [67]. The value of sirolimus in GVHD prophylaxis
has also been extended to the reduced intensity setting
[68,69]. HLA-haploidentical transplantation [70], um-
bilical cord blood transplantation (UCBT), [71], and
pediatric transplantation [72]. Regimens that have
tested sirolimus in combination with MMF rather
than FK-506 also appear to be promising [73], whereasa combination evaluating everolimus appeared
less so [74].
Despite an increase in an incidence of endothe-
lial-related injuries, the combination of sirolimus
and FK-506 is associated with improved OS and a re-
duction in TRM [66]. One of the more striking dif-
ferences associated with this combination is the
reduction in oropharyngeal mucositis, which is 1 of
the most serious patient-reported adverse effects re-
lated to transplantation [75]. In a case-control study,
the incidence and severity of mucositis was reduced,
the use of parenteral nutrition was reduced, and pa-
tients required less narcotic analgesia when com-
pared with patients who received MTX for GVHD
prophylaxis [37]. Thus, there appears to be a reduc-
tion in GVHD and morbidity after transplantation
with this regimen.
The issue of whether sirolimus-based GVHD pro-
phylaxis is better than FK-506 and MTX is currently
being addressed in a randomized, controlled trial con-
ducted by the bone marrow transplant - clinical trials
network (BMT-CTN) (BMT) CTN. This trial will
enroll 312 patients and attempt to demonstrate
a 15% improvement in GVHD-free survival at 114
days from the time of transplantation. This endpoint
was chosen to highlight both the improved rate of
GVHD prophylaxis as well as the reduction in TRM
seen in prior clinical trials.Elimination of Calcineurin Inhibitors and MTX
Cy
Posttransplant Cy was used initially in the 1980s
to prevent GVHD via inhibition of rapidly dividing
T cells in a manner similar to MTX [76]. Stem cells
contain high levels of aldehyde dehydrogenase which
converts 4-hydroxycyclophosphamide into a nonalky-
lating metabolite, thus sparing the stem cell from the
antiproliferative activity of this agent. In addition,
the GI epithelium also contains high levels of alde-
hyde dehydrogenase, thus affording a protective ef-
fect against gastrointestinal mucositis when this
cytotoxic agent is given shortly after intensive condi-
tioning regimens. The Hopkins group is testing the
use of high-dose, posttransplantation Cy as sole pro-
phylaxis of GVHD after HLA-matched BMT [77].
Cy is given at a dose of 50 mg/kg on days 3 and 4
after transplantation, after oral Bu and Cy (100
mg/kg total) conditioning in patients with advanced
hematologic malignancies. Over 100 patients have
been treated in this manner, with bone marrow as
the preferred stem cell source (unpublished data
kindly provided by L. Luznik). The median time to
neutrophil engraftment in this experience is 23 days
(MRD donors, n 5 78) and 25 days (URD, n 5
39), without the use of exogenous colony stimulating
S24 Biol Blood Marrow Transplant 16:S18-S27, 2010R. Storb et al.factors. Grade II-IV aGVHD occurred in 41%
(MRD) and 46% (MUD) of patients; however, grade
III-IV GVHD was uncommon, occurring in 11%
and 8% of patients, respectively. This regimen was
very safe as the treatment-related mortality rates at
100 days were 6% and 13% for MRD and MUD re-
cipients, respectively. With a median follow-up of 26
months among surviving patients, the cumulative in-
cidence of cGVHD is only 10%. OS exceeds 50% at
2 years in a group of patients with advanced malig-
nancies. As predicted, oropharyngeal mucositis was
not severe and was reduced in comparison with
a CsA and MTX cohort (personal communication,
E. Fuchs). Although GVHD rates here appear simi-
lar to historic controls, this regimen with surpris-
ingly low toxicity may also be considered an
alternative to MTX after transplantation, and de-
serves to be tested in a randomized trial. In haploi-
dentical transplantation, supplemental FK-506 is
being administered.
With the recent elevation of cGVHD as a major
concern in allogeneic transplantation, it will become
important to develop GVHD prophylaxis regimens
that address this concern as well. There is mounting
evidence demonstrating the important role of
CD41CD251FoxP31 T cells (regulatory T cells) in
the pathophysiology of cGVHD [78-80]. Regulatory
T cell function is dependent on IL-2 [81-83], and be-
cause calcineurin inhibitors act by inhibiting the T cell
response to IL-2, calcineurin inhibitors are far more
damaging to regulatory T cell populations than drugs
such as sirolimus or MMF [84,85]. The autoimmune
manifestations of cGVHD have been linked to the fail-
ure of clonal deletion induced by calcineurin inhibi-
tion [86], suggesting that early exposure to these
agents may, in fact, be deleterious for prevention of
cGVHD. Thus, strategies that increase regulatory T
cell numbers or function may be associated with a re-
duction in cGVHD. In the German experience using
sirolimus, MMF, and ATG, in addition to low rates
of aGVHD, the rate of cGVHD was similarly low
(30%), although it is difficult to attribute this to the
lack of the calcineurin inhibitor or the use of ATG in
the preparative regimen [73].SUMMARYAND FUTURE DIRECTIONS
There are numerous strategies that have been dem-
onstrated to be effective in prevention against aGVHD.
In smaller randomized trials, many of these approaches
have been shown to be equivalent or superior, in some
respects, when compared with the standard of CsA and
MTX, although larger randomized trials are required
for establishment of a new standard of care. The need
is for an effective regimen that eliminates both aGVHD
and cGVHD, allows effective immunologic recovery,
and maintains graft-versus-leukemia effects.ACKNOWLEDGMENTS
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